ALGS
What one share of Aligos Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections (e.g., SARS‑CoV‑2, SARS‑CoV, MERS‑CoV, and other related infections).
Aligos Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.36 |
|---|---|
| Profit | −$7.31 |
| Cash and investments | $4.87 |
| Book value | $5.11 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$650.97 | $34.70 | −$617.20 | — | −$413.02 |
| 2020 | $0.00 | −$271.68 | $5.17 | −$191.04 | — | — |
| 2021 | $0.00 | −$80.50 | $0.56 | −$73.11 | — | $108.18 |
| 2022 | $0.00 | −$56.24 | $0.55 | −$47.04 | — | $60.52 |
| 2023 | $2.42 | −$34.20 | $0.01 | −$30.82 | — | $30.65 |
| 2024 | $0.58 | −$20.94 | $0.02 | −$12.91 | — | −$7.50 |
| 2025 | $0.22 | −$2.45 | — | −$8.35 | — | $8.67 |